The prognostic value of the HALP score among patients diagnosed with Hodgkin lymphoma
- 1Department of Hematology, University of Health Sciences, Istanbul Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey
- 2Department of Hematology, University of Health Sciences, Tepecik Training and Research Hospital, Turkey.
Abstract
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is an immune-nutritional biomarker utilized for prognostic assessment in oncology patients. It is determined by the formula: hemoglobin (g/L) × albumin (g/L) × lymphocytes (×109/L)]/platelets (×109/L). The objective of this study is to evaluate the prognostic value of the HALP score and its association with treatment response and survival outcomes among patients diagnosed with Hodgkin lymphoma (HL). Patients diagnosed with HL at the Hematology Clinic of Istanbul Başakşehir Çam and Sakura City Hospital between January 1, 2020, and January 1, 2025, were included in this study. A total of 100 patients with HL were included in the study. Patients were categorized based on the median HALP score of 23.72. Patients with a low HALP score exhibited significantly higher rates of stage IV disease, presence of B symptoms, and bulky masses. Patients with a high HALP score demonstrated significantly more complete response and less progression at the end of treatment. The analysis revealed a statistically significant 2.82-fold (95% confidence intervals: 1.14–6.97) increased risk of progression in patients with a HALP score of <23.72 compared to those with a score of ≥23.72. Patients with lower HALP scores exhibited more adverse disease characteristics. Lower HALP scores were associated with adverse disease characteristics, poorer treatment response, and shorter progression-free survival; however, HALP did not remain an independent prognostic factor in multivariate analysis.
Related
- Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial
- The Comparative Prognostic Value of the Interim PET Deauville Score and ΔSUVmax in Classical Hodgkin Lymphoma: A Real-World Study of Imaging and Inflammatory Markers
- Pretreatment Prognostic Nutritional Index Is Associated with Treatment Response and Survival in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Receiving CAR-T Cell Therapy
- The prognostic value of KRAS, NRAS, and BRAF genes mutations in patients with newly diagnosed multiple myeloma.
- Prognostic value of C-reactive protein-albumin-lymphocyte (CALLY) score and CRP-albumin ratio on mortality in patients diagnosed with pulmonary thromboembolism
BibTeX
@article{ayer2026prognostic,
title = {{The prognostic value of the HALP score among patients diagnosed with Hodgkin lymphoma}},
author = {Mesut Ayer and Gunhan Tekin and Edibe Sevde Eker and Istemi Serin},
journal = {Medicine},
year = {2026},
month = oct,
doi = {10.1097/md.0000000000051347},
url = {https://europepmc.org/article/PMC/PMC13727272},
note = {CC BY},
}
RIS
TY - JOUR
TI - The prognostic value of the HALP score among patients diagnosed with Hodgkin lymphoma
AU - Mesut Ayer
AU - Gunhan Tekin
AU - Edibe Sevde Eker
AU - Istemi Serin
PY - 2026
DA - 2026/10/30
JO - Medicine
DO - 10.1097/md.0000000000051347
UR - https://europepmc.org/article/PMC/PMC13727272
AB - The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is an immune-nutritional biomarker utilized for prognostic assessment in oncology patients. It is determined by the formula: hemoglobin (g/L) × albumin (g/L) × lymphocytes (×109/L)]/platelets (×109/L). The objective of this study is to evaluate the prognostic value of the HALP score and its association with treatment response and survival outcomes among patients diagnosed with Hodgkin lymphoma (HL). Patients diagnosed with HL at the Hematology Clinic of Istanbul Başakşehir Çam and Sakura City Hospital between January 1, 2020, and January 1, 2025, were included in this study. A total of 100 patients with HL were included in the study. Patients were categorized based on the median HALP score of 23.72. Patients with a low HALP score exhibited significantly higher rates of stage IV disease, presence of B symptoms, and bulky masses. Patients with a high HALP score demonstrated significantly more complete response and less progression at the end of treatment. The analysis revealed a statistically significant 2.82-fold (95% confidence intervals: 1.14–6.97) increased risk of progression in patients with a HALP score of <23.72 compared to those with a score of ≥23.72. Patients with lower HALP scores exhibited more adverse disease characteristics. Lower HALP scores were associated with adverse disease characteristics, poorer treatment response, and shorter progression-free survival; however, HALP did not remain an independent prognostic factor in multivariate analysis.
SN - 0304-5412
SN - 1536-5964
SN - 0025-7974
ER -